NeurologyLive® Friday 5 — May 23, 2025

Author(s):

Key Takeaways

Hormonal changes significantly impact sleep disorders in women, as discussed by Suzanne Bertisch, MD, highlighting the need for tailored approaches.
Luis Querol, MD, PhD, shares insights on riliprubart's sustained responses and biomarker findings in CIDP, emphasizing its potential therapeutic impact.
Claudia Sommer, MD, explains riliprubart's mechanism as a targeted complement inhibitor, offering a more selective immune approach for CIDP treatment.
Brad Kamitaki, MD, focuses on improving dementia care in Asian and Pacific American communities, highlighting RCASIA's mission and key takeaways from AAN 2025.
Continuous subcutaneous infusion systems are discussed as strategic options for managing advanced Parkinson's disease, particularly for patients with motor fluctuations.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 23, 2025.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Hormonal Influences on Sleep Disorders in Women: Suzanne Bertisch, MD

The chair of the Women’s Sleep Health Task Force at the American Academy of Sleep Medicine talked about how hormonal changes across a woman’s lifespan influence the prevalence of sleep disorders. [WATCH TIME: 4 minutes]

2: Biomarker and Subgroup Insights on Novel CIDP Therapy Riliprubart: Luis Querol, MD, PhD

The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, provided clinical context on sustained responses and new biomarker findings from exploratory phase 2 data on riliprubart in CIDP. [WATCH TIME: 4 minutes]

3: A More Selective Immune Approach to CIDP With Riliprubart: Claudia Sommer, MD

The president-elect of the Peripheral Nerve Society provided clinical context the mechanism and clinical relevance of riliprubart, a targeted complement inhibitor in development for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 3 minutes]

4: NeuroVoices: Brad Kamitaki, MD, on Aiming to Improve Dementia Care in Asian and Pacific American Communities

The assistant professor of neurology at Robert Wood Johnson Medical School discussed the mission of RCASIA, highlights from its annual retreat, and key takeaways from AAN 2025.

5: Place of Continuous Subcutaneous Infusion Systems in Parkinson Disease Management

Panelists discuss how continuous subcutaneous infusion systems should be strategically positioned within Parkinson disease management, typically as options for patients with advanced disease experiencing motor fluctuations despite optimized oral therapy.